A View LCS vs AI-CVD

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 70/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

A View LCS

by Coreline Soft

AI-CVD

by HeartLung AI

AI Verdict

Both A View LCS and AI-CVD are FDA-cleared AI platforms that perform cardiovascular risk assessment, including Coronary Artery Calcium (CAC) scoring, from existing CT scans. However, A View LCS offers a broader comprehensive thoracic analysis, integrating lung cancer screening and emphysema quantification alongside cardiac features, making it suitable for pulmonary and cardiac assessments. AI-CVD, on the other hand, focuses more deeply on opportunistic screening for a wider range of cardiovascular and multisystem diseases, providing detailed analysis of various cardiac structures and extending its utility to chest and abdominal CTs.

Choose A View LCS if…

Choose AVIEW LCS if your primary objective is a comprehensive, dedicated thoracic CT analysis, especially within a structured lung cancer screening program. This tool is optimized for detailed lung nodule detection, classification, and volume quantification, alongside emphysema assessment and precise coronary artery calcification scoring, all from a single low-dose CT scan. It is best suited for workflows where a specific thoracic CT is performed for screening and detailed diagnostic insights are required.

View A View LCS →

Choose AI-CVD if…

Choose AI-CVD if you are looking to implement an opportunistic screening program to identify cardiovascular and multisystem diseases using existing CT scans. This platform excels at leveraging previously acquired chest and abdominal CTs to detect hidden risks such as coronary artery calcium, aortic valve calcification, and abnormal cardiac chamber volumes, without necessitating additional imaging, radiation, or changes to current clinical workflows. It is ideal for maximizing the diagnostic value of routine CTs already in your system.

View AI-CVD →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	A View LCS	AI-CVD
Deployment	Cloud-based, Hybrid solution, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker). It can also be integrated into standard reading environments (PACS), RIS (Radiological Information System), or used as a standalone third-party application or web-based application.	Unknown
FDA Status	Cleared AI-estimated	Unknown
HIPAA	Yes AI-estimated	Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

A View LCS

Tool A offers greater flexibility with multiple deployment options (Cloud, Hybrid, Local dedicated, Local virtualized), catering to diverse IT infrastructures. Its automated comprehensive report generation in various formats (PDF, DICOM PDF, SR) also enhances integration into existing clinical workflows, contributing to better overall usability.

Clinical Value

A View LCS

Tool A provides a broader 'comprehensive thoracic CT analysis' from a single low-dose CT scan, encompassing automated lung nodule detection with Lung-RADS scoring, emphysema quantification, and coronary artery calcification (CAC) scoring. This integrated approach offers a wider range of clinical insights into lung cancer, COPD, and cardiovascular disease from one examination.

Pricing & Value

Tie

Both tools require direct contact with the vendor for pricing information, making it impossible to conduct a head-to-head comparison of their cost-effectiveness or overall value proposition. Both aim to provide significant clinical value by leveraging imaging data for early disease detection.

Enterprise Readiness

A View LCS

Tool A explicitly states HIPAA compliance and the availability of a Business Associate Agreement (BAA), which are crucial for enterprise adoption and data security. Additionally, its multiple deployment options (Cloud, Hybrid, Local) offer greater flexibility for integration into various hospital IT environments compared to Tool B's cloud-only deployment.

Innovation

Tie

Both tools demonstrate significant innovation. Tool A's ability to perform comprehensive thoracic analysis for multiple conditions from a single low-dose CT scan, coupled with its CT kernel conversion AI technology, is highly innovative. Tool B's focus on opportunistic screening from *existing* CT scans, enabling early detection of multisystem diseases without additional procedures, represents a groundbreaking application of AI in preventive medicine.

Support & Docs

Tie

Neither the provided structured facts nor a general web search yielded specific details regarding the level of customer support or the availability of comprehensive public documentation for either tool. Without this information, it is not possible to distinguish between them on this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	A View LCS	AI-CVD
Name	A View LCS	AI-CVD
Company	Coreline Soft Co.	HeartLung Corporation
Categories	Cardiology AI, Oncology AI, Radiology & Imaging AI	Cardiology AI
Key Features (Cardiology)	Coronary Artery Calcium (CAC) scoring (Agatston, volume, mass), Segmentation of major coronary arteries	Coronary Artery Calcium (CAC) scoring, Aortic wall, aortic valve, and mitral valve calcium analysis, Cardiac chamber volumetry (Left Atrium, Left Ventricle, Right Atrium, Right Ventricle), Epicardial fat volumetry, Aorta and pulmonary artery sizing
Key Features (Pulmonology/Thoracic)	Automated lung nodule detection and classification, Nodule volume quantification and measurement (3D), Lung-RADS scoring and reporting, Emphysema analysis and quantification (LAA)	Not specified

Videos

Demos, reviews, and walkthroughs featuring A View LCS and AI-CVD.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What are the primary differences in the types of diseases each tool screens for?

AVIEW LCS specializes in comprehensive thoracic CT analysis, including lung cancer screening, emphysema quantification, and coronary artery calcification detection. AI-CVD focuses on opportunistic screening for cardiovascular and multisystem diseases, such as coronary heart disease, heart failure, atrial fibrillation, stroke, osteoporosis, liver steatosis, and diabetes, using existing CT scans.

How do the tools differ in their approach to utilizing CT scans?

AVIEW LCS performs comprehensive analysis from a single low-dose thoracic CT scan, providing automated detection and quantification of various findings. AI-CVD specializes in opportunistic screening by extracting information from existing chest and abdominal CT scans, aiming to detect hidden health risks without requiring additional imaging, radiation, contrast, or workflow disruption.

What specific cardiac measurements and analyses does each tool provide beyond basic Coronary Artery Calcium (CAC) scoring?

AVIEW LCS offers CAC scoring (Agatston, volume, mass) and segmentation of major coronary arteries. AI-CVD provides CAC scoring, along with analysis of aortic wall, aortic valve, and mitral valve calcium, cardiac chamber volumetry (Left Atrium, Left Ventricle, Right Atrium, Right Ventricle), epicardial fat volumetry, and aorta and pulmonary artery sizing.

Does either tool offer capabilities for lung nodule detection or emphysema quantification?

Yes, AVIEW LCS offers automated lung nodule detection and classification, nodule volume quantification, Lung-RADS scoring and reporting, and emphysema analysis and quantification (LAA). AI-CVD includes lung attenuation analysis, but does not explicitly list lung nodule detection or emphysema quantification as key features.

What kind of reporting capabilities do these tools offer?

AVIEW LCS provides automated comprehensive report generation in PDF, DICOM PDF, and SR formats, including Lung-RADS scoring and detailed nodule information. AI-CVD provides automated CT-derived anatomical and density-based measurements, with volumetric measurements adjusted for body surface area and reported in absolute values and population-based percentiles.